Literature DB >> 2833435

Genetic control of CTL responses to AKR/Gross virus: effect of inheritance of Akv proviruses.

W R Green1, R F Rich.   

Abstract

Our earlier observations suggested that the AKR/Gross leukemia virus-specific C57BL/6 cytolytic T lymphocyte (CTL) response was directed to Akv-1, but not Akv-3 or Akv-4, provirus-associated determinants. Based on these data, the present experiments were performed with various AKXL RI mouse strains of the responder H-2b haplotype which had inherited different combinations of the Akv-1, -3, and -4 proviruses, to determine whether these strains were able to mount specific antiviral CTL responses. In a comparison with control responder C57BL/6 mice, a clear pattern emerged. Akv-negative mice of the AKXL-29 strain were fully responsive, but five other AKXL strains which had inherited the Akv-1 provirus failed to mount significant antiviral CTL responses (less than or equal to 10% of control). In contrast, an Akv-1-negative but Akv-4-positive strain (AKXL-5) was partially responsive (approximately 24% of the C57BL/6 control). These results were consistent with a direct relationship between the Akv-1 provirus and the nominal antigens recognized by antiviral CTL, and with an inverse correlation between in vivo expression of viral antigens by normal cells and the ability to generate antiviral CTL. The possible mechanisms accounting for this unresponsiveness are discussed along with the utility of this system for investigating the interactions of retroviruses with the immune system.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2833435     DOI: 10.1007/BF00395125

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  21 in total

1.  Clonal heterogeneity of anti-AKR/gross leukemia virus cytotoxic T lymphocytes. Evidence for two distinct antigen systems.

Authors:  H Azuma; J D Phillips; W R Green
Journal:  J Immunol       Date:  1987-10-01       Impact factor: 5.422

2.  The role of genetics in Gross virus leukemogenesis.

Authors:  F Lilly
Journal:  Bibl Haematol       Date:  1970

3.  Cytolytic T lymphocyte-defined retroviral antigens on normal cells: encoding by the Akv-1 proviral locus.

Authors:  W R Green; R F Graziano
Journal:  Immunogenetics       Date:  1986       Impact factor: 2.846

4.  The generation and specificity of cytotoxic T cells raised against syngeneic tumor cells bearing AKR/Gross murine leukemia virus antigens.

Authors:  W R Green; R C Nowinski; C S Henney
Journal:  J Exp Med       Date:  1979-07-01       Impact factor: 14.307

5.  Cell surface expression of cytotoxic T lymphocyte-defined, AKR/Gross leukemia virus-associated tumor antigens by normal AKR.H-2b splenic B cells.

Authors:  W R Green
Journal:  J Immunol       Date:  1983-12       Impact factor: 5.422

6.  Host-range restrictions of murine leukemia viruses in mouse embryo cell cultures.

Authors:  J W Hartley; W P Rowe; R J Huebner
Journal:  J Virol       Date:  1970-02       Impact factor: 5.103

7.  Immune response genes control T killer cell response against Moloney tumor antigen cytolysis regulating reactions against the best available H-2 + viral antigen association.

Authors:  E Gomard; Y Hénin; M J Colombani; J P Lévy
Journal:  J Exp Med       Date:  1980-06-01       Impact factor: 14.307

8.  Correlation of early murine leukemia virus titer and H-2 type with spontaneous leukemia in mice of the BALB/c times AKR cross: a genetic analysis.

Authors:  F Lilly; M L Duran-Reynals; W P Rowe
Journal:  J Exp Med       Date:  1975-04-01       Impact factor: 14.307

9.  H-2D control of recovery from Friend virus leukemia: H-2D region influences the kinetics of the T lymphocyte response to Friend virus.

Authors:  W J Britt; B Chesebro
Journal:  J Exp Med       Date:  1983-06-01       Impact factor: 14.307

10.  A major genetic locus affecting resistance to infection with murine leukemia viruses. 3. Assignment of the Fv-1 locus to linkage group 8 of the mouse.

Authors:  W P Rowe; J B Humphrey; F Lilly
Journal:  J Exp Med       Date:  1973-03-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.